DK3245193T3 - Heterocycliske forbindelser til billedscanning og behandling af cancer samt fremgangsmåder til anvendelse af disse - Google Patents
Heterocycliske forbindelser til billedscanning og behandling af cancer samt fremgangsmåder til anvendelse af disse Download PDFInfo
- Publication number
- DK3245193T3 DK3245193T3 DK16736999.0T DK16736999T DK3245193T3 DK 3245193 T3 DK3245193 T3 DK 3245193T3 DK 16736999 T DK16736999 T DK 16736999T DK 3245193 T3 DK3245193 T3 DK 3245193T3
- Authority
- DK
- Denmark
- Prior art keywords
- cancer
- procedures
- treatment
- heterocyclic compounds
- image scanning
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0465—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562102719P | 2015-01-13 | 2015-01-13 | |
PCT/CA2016/000008 WO2016112455A1 (en) | 2015-01-13 | 2016-01-13 | Heterocyclic compounds for cancer imaging and treatment and methods for their use |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3245193T3 true DK3245193T3 (da) | 2022-03-07 |
Family
ID=56405073
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16736999.0T DK3245193T3 (da) | 2015-01-13 | 2016-01-13 | Heterocycliske forbindelser til billedscanning og behandling af cancer samt fremgangsmåder til anvendelse af disse |
Country Status (11)
Country | Link |
---|---|
US (3) | US10654811B2 (da) |
EP (2) | EP3988541A1 (da) |
JP (2) | JP6884100B2 (da) |
AU (2) | AU2016206412B2 (da) |
CA (1) | CA2973036A1 (da) |
DK (1) | DK3245193T3 (da) |
ES (1) | ES2907708T3 (da) |
HU (1) | HUE057962T2 (da) |
IL (2) | IL253394B (da) |
NZ (1) | NZ733343A (da) |
WO (1) | WO2016112455A1 (da) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2010014372A (es) | 2008-07-02 | 2011-06-20 | British Columbia Cancer Agency | Agentes terapeuticos derivados de eter diglicidico y métodos para su uso. |
DK3245193T3 (da) | 2015-01-13 | 2022-03-07 | British Columbia Cancer Agency Branch | Heterocycliske forbindelser til billedscanning og behandling af cancer samt fremgangsmåder til anvendelse af disse |
US10471023B2 (en) | 2015-03-12 | 2019-11-12 | British Columbia Cancer Agency Branch | Bisphenol ether derivatives and methods for using the same |
US20170298033A1 (en) | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
CN107337612B (zh) * | 2017-06-15 | 2019-06-18 | 杭州科兴生物化工有限公司 | 双酚类化合物及其制备方法和在制备抗肿瘤药物中的应用 |
CN109772352B (zh) * | 2017-11-14 | 2021-08-31 | 中国石油化工股份有限公司 | 一种制备1,4-丁炔二醇联产丙炔醇的催化剂及其制备方法和应用 |
US11485713B2 (en) | 2018-05-25 | 2022-11-01 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
SG11202103325WA (en) * | 2018-10-18 | 2021-05-28 | Essa Pharma Inc | Androgen receptor modulators and methods for their use |
US20230078913A1 (en) * | 2019-03-28 | 2023-03-16 | Essa Pharma, Inc. | Androgen receptor modulators and methods for use as proteolysis targeting chimera ligands |
CA3134545A1 (en) * | 2019-03-28 | 2020-10-01 | Essa Pharma, Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
CA3174422A1 (en) | 2020-04-17 | 2021-10-21 | Essa Pharma, Inc. | Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof |
WO2022060969A1 (en) * | 2020-09-16 | 2022-03-24 | Essa Pharma, Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
CA3215182A1 (en) * | 2021-04-16 | 2022-10-20 | Han-Jie Zhou | Pharmaceutical compositions comprising inhibitors of the androgen receptor and uses thereof |
WO2023046283A1 (en) | 2021-09-22 | 2023-03-30 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Compounds and their use in a method for modulating ar (androgen receptor) transcriptional activity |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2571217A (en) | 1951-10-16 | Horace s | ||
US2890189A (en) | 1954-06-14 | 1959-06-09 | Johnson & Son Inc S C | Alkali soluble resins and compositions containing the same |
US3074974A (en) | 1957-12-06 | 1963-01-22 | Monsanto Chemicals | Method for the preparation of diglycidyl ether of tetrachlorobisphenol-a |
US3162615A (en) | 1961-01-03 | 1964-12-22 | Dow Chemical Co | Polyesters from cyclic polyhaloalkane polyols and unsaturated dicarboxylic acids |
FR1389005A (fr) | 1963-01-09 | 1965-02-12 | Bayer Ag | Procédé perfectionné pour durcir des polyépoxydes |
SU638596A1 (ru) | 1975-09-01 | 1978-12-25 | Государственный Научно-Исследовательский И Проектный Институт Полимерных Клеев Им. Э.Л.Тер-Газаряна | Хлоргидриднное производное диаллилизоциануровой кислоты в качестве пластификатора поливинилацетатной эмульсии |
US4284574A (en) | 1979-06-15 | 1981-08-18 | Ciba-Geigy Corporation | Diglycidyl ethers of di-secondary alcohols, their preparation, and curable compositions containing them |
SU929630A1 (ru) | 1980-02-06 | 1982-05-23 | Научно-Исследовательский Институт Биологии При Иркутском Государственном Университете Им.А.А.Жданова | Способ получени ди-или триоксидифенил-сульфонов |
US4369298A (en) | 1980-05-27 | 1983-01-18 | Tokuyama Soda Kabushiki Kaisha | Novel cured resin, process for production thereof, and lens composed of said resin from bis(alkyleneoxyphenyl)-diacrylate, bis(alkyleneoxyphenyl)diallyl ether, bis(alkyleneoxyphenyl)diallyl carbonate monomers |
DE3170223D1 (en) | 1981-01-13 | 1985-06-05 | Teijin Ltd | Ion-permeable composite membrane and its use in selective separation |
IN169231B (da) | 1984-03-15 | 1991-09-14 | Ciba Geigy Ag | |
PL141793B1 (en) | 1984-10-08 | 1987-08-31 | Politechnika Warszawska | Method of obtaining bisphenolic resins |
US5753730A (en) | 1986-12-15 | 1998-05-19 | Mitsui Toatsu Chemicals, Inc. | Plastic lenses having a high-refractive index, process for the preparation thereof and casting polymerization process for preparing sulfur-containing urethane resin lens and lens prepared thereby |
JPH0832844B2 (ja) | 1987-02-09 | 1996-03-29 | パイロツトインキ株式会社 | 筆記板用不透明性インキ |
CA1311322C (en) | 1987-04-27 | 1992-12-08 | Morio Gaku | Thermosetting resin composition |
US5155196A (en) | 1987-06-01 | 1992-10-13 | The Dow Chemical Company | Polymer resulting from the cure of a preformed chromene-containing mixture |
KR910003821B1 (ko) | 1987-06-01 | 1991-06-12 | 더 다우 케미칼 캄파니 | 하이드록시방향족 화합물의 프로파르길 에테르를 제조하는 방법 |
JP2572020B2 (ja) | 1987-06-19 | 1997-01-16 | 竹本油脂株式会社 | 熱硬化性樹脂用難燃剤 |
DE3821585A1 (de) | 1987-09-13 | 1989-03-23 | Hoechst Ag | Positiv arbeitendes strahlungsempfindliches gemisch und daraus hergestelltes strahlungsempfindliches aufzeichnungsmaterial fuer hochenergetische strahlung |
US4855184A (en) | 1988-02-02 | 1989-08-08 | Minnesota Mining And Manufacturing Company | Radiation-curable protective coating composition |
DE3939760A1 (de) | 1989-12-01 | 1991-06-06 | Bayer Ag | Verfahren zur lackierung von kunststoffen, lackierte kunststoffe und die verwendung von hierzu geeigneten haftvermittlern |
EP0515128A1 (en) | 1991-05-23 | 1992-11-25 | Konica Corporation | Silver halide color photographic light-sensitive material |
JPH0649473A (ja) | 1992-08-04 | 1994-02-22 | Asahi Chem Ind Co Ltd | 冷媒組成物 |
DE4323512A1 (de) | 1992-09-01 | 1994-04-28 | Agfa Gevaert Ag | Fotografisches Aufzeichnungsmaterial |
JPH07117349A (ja) | 1993-10-27 | 1995-05-09 | Asahi Denka Kogyo Kk | 感熱記録材料 |
EP0794771A1 (en) * | 1994-11-29 | 1997-09-17 | Hoechst Marion Roussel, Inc. | Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis |
DE19526146A1 (de) * | 1995-07-07 | 1997-01-09 | Schering Ag | Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln |
JPH09176240A (ja) | 1995-12-27 | 1997-07-08 | Mitsubishi Chem Corp | 光重合性組成物 |
JPH10133427A (ja) | 1996-11-05 | 1998-05-22 | Fuji Xerox Co Ltd | 静電潜像現像用キャリア、静電潜像現像剤及び画像形成方法 |
AR011626A1 (es) | 1997-02-07 | 2000-08-30 | Shell Int Research | Un procedimiento para la elaboracion de compuestos epoxidos, resinas epoxidas obtenidas mediante dicho procedimiento y un procedimiento para laelaboracion de compuestos intermedios para la elaboracion de compuestos epoxidos |
JPH10316803A (ja) | 1997-05-16 | 1998-12-02 | Teijin Chem Ltd | 難燃性樹脂組成物 |
IL125840A (en) | 1997-08-22 | 2002-12-01 | Teijin Chemicals Ltd | Bromine compound production method |
JPH11166087A (ja) | 1997-12-04 | 1999-06-22 | Teijin Chem Ltd | 難燃性樹脂組成物 |
CA2302169A1 (en) | 1998-06-30 | 2000-01-13 | The University Of British Columbia | Inhibitors of androgen-independent activation of androgen receptor |
US6245117B1 (en) | 1998-08-07 | 2001-06-12 | Ipposha Oil Industries Co., Ltd. | Modifier of cellulose fibers and modification method of cellulose fibers |
US6218430B1 (en) | 1998-08-24 | 2001-04-17 | Ligand Pharmaceuticals Incorporated | Vitamin D3 mimics |
JP3795679B2 (ja) | 1998-09-01 | 2006-07-12 | 帝人化成株式会社 | 臭素化合物の製造方法 |
WO2001027622A1 (en) | 1999-10-14 | 2001-04-19 | Bristol-Myers Squibb Company | Crystallographic structure of the androgen receptor ligand binding domain |
US6534621B2 (en) | 2000-05-18 | 2003-03-18 | Dow Global Technologies Inc. | Process for manufacturing a hydroxyester derivative intermediate and epoxy resins prepared therefrom |
US6472436B1 (en) | 2000-07-17 | 2002-10-29 | The Salk Institute For Biological Studies | Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production |
WO2002018334A2 (en) | 2000-08-31 | 2002-03-07 | Theravance, Inc. | Sodium channel modulators |
US6646102B2 (en) | 2001-07-05 | 2003-11-11 | Dow Global Technologies Inc. | Process for manufacturing an alpha-dihydroxy derivative and epoxy resins prepared therefrom |
US20030092724A1 (en) | 2001-09-18 | 2003-05-15 | Huaihung Kao | Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic |
WO2003074450A2 (en) | 2002-02-28 | 2003-09-12 | The University Of Tennessee Research Corporation | Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy |
GB0324551D0 (en) | 2003-10-21 | 2003-11-26 | Karobio Ab | Novel compounds |
EP1687258A2 (en) | 2003-11-20 | 2006-08-09 | Eli Lilly And Company | Vitamin d receptor modulators |
JP2007524677A (ja) | 2004-02-13 | 2007-08-30 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | 放射性標識化合物及び組成物、それらの前駆体及びそれらの製造方法 |
JP2005325301A (ja) | 2004-05-17 | 2005-11-24 | Fuji Photo Film Co Ltd | セルロースアシレートドープ組成物、およびセルロースアシレートフィルム |
MX2007001993A (es) | 2004-08-18 | 2007-05-10 | Warner Lambert Co | Moduladores de androgenos. |
JP2006208607A (ja) | 2005-01-26 | 2006-08-10 | Fuji Photo Film Co Ltd | パターン形成材料、並びにパターン形成装置及び永久パターン形成方法 |
JP4753601B2 (ja) | 2005-03-23 | 2011-08-24 | 旭化成イーマテリアルズ株式会社 | 感光性組成物 |
EP1717235A3 (en) | 2005-04-29 | 2007-02-28 | Bioprojet | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands |
FR2885904B1 (fr) | 2005-05-19 | 2007-07-06 | Aventis Pharma Sa | Nouveaux derives du fluorene, compositions les contenant et utilisation |
EP1792622A1 (en) | 2005-11-11 | 2007-06-06 | GPC Biotech AG | Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and EGFR inhibitors or pyrimidine analogues |
JP2007290980A (ja) | 2006-04-21 | 2007-11-08 | Shin Etsu Chem Co Ltd | 含フッ素(メタ)アクリル酸エステル |
DE102006019044A1 (de) | 2006-04-25 | 2007-10-31 | Merck Patent Gmbh | Antioxidantien |
TW200819421A (en) | 2006-10-31 | 2008-05-01 | Univ Nat Chunghsing | The method of synthesizing biphenol A, BPA having di-alkoxyl group by using polycarbonate or its waste |
KR20090115797A (ko) | 2007-02-20 | 2009-11-06 | 바스프 에스이 | 고굴절률 단량체, 이의 조성물 및 용도 |
MX2010014372A (es) | 2008-07-02 | 2011-06-20 | British Columbia Cancer Agency | Agentes terapeuticos derivados de eter diglicidico y métodos para su uso. |
JP2011530511A (ja) | 2008-08-05 | 2011-12-22 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療用化合物 |
AR079975A1 (es) | 2010-01-06 | 2012-03-07 | British Columbia Cancer Agency | Agentes terapeuticos derivados de bisfenol u metodos para su uso, composiciones farmaceuticas y uso de los mismos |
JP5940982B2 (ja) | 2010-01-06 | 2016-06-29 | ブリティッシュ コロンビア キャンサー エージェンシー ブランチ | アンドロゲンレセプター活性調節因子としての、ビスフェノール誘導体およびその使用 |
EP2693875A4 (en) | 2011-04-08 | 2014-10-22 | British Columbia Cancer Agency | BISPHENOL COMPOUNDS AND METHODS OF USE |
WO2012145328A1 (en) | 2011-04-18 | 2012-10-26 | The University Of British Columbia | Dibenzylphenyl compounds and methods for their use |
WO2012145330A1 (en) | 2011-04-18 | 2012-10-26 | The University Of British Columbia | Fluorene-9-bisphenol compounds and methods for their use |
EP2744773B1 (en) | 2011-08-19 | 2016-11-02 | British Columbia Cancer Agency Branch | Fluorinated bisphenol ether compounds and methods for their use |
WO2013028791A1 (en) | 2011-08-22 | 2013-02-28 | British Columbia Cancer Agency Branch | 18f compounds for cancer imaging and methods for their use |
US9365510B2 (en) * | 2012-04-16 | 2016-06-14 | British Columbia Cancer Agency Branch | Aziridine bisphenol ethers and related compounds and methods for their use |
JP6100439B2 (ja) * | 2013-05-10 | 2017-03-22 | ブリティッシュ コロンビア キャンサー エージェンシー ブランチ | アンドロゲン受容体調節薬のエステル誘導体およびそれらの使用のための方法 |
CN103342892A (zh) | 2013-06-06 | 2013-10-09 | 西安交通大学 | 一种双马来酰亚胺树脂的增韧改性剂及其制备方法 |
US20150010469A1 (en) | 2013-07-03 | 2015-01-08 | British Columbia Cancer Agency Branch | Bisphenol ether compounds with novel bridging groups and methods for their use |
AU2014317753A1 (en) | 2013-09-09 | 2016-04-07 | British Columbia Cancer Agency Branch | Halogenated compounds for cancer imaging and treatment and methods for their use |
WO2016058082A1 (en) | 2014-10-14 | 2016-04-21 | British Columbia Cancer Agency Branch | 18f compounds for cancer imaging and methods for their use |
WO2016058080A1 (en) | 2014-10-14 | 2016-04-21 | British Columbia Cancer Agency Branch | Fluoro-chloro bisphenol ether compounds and methods for their use |
DK3245193T3 (da) | 2015-01-13 | 2022-03-07 | British Columbia Cancer Agency Branch | Heterocycliske forbindelser til billedscanning og behandling af cancer samt fremgangsmåder til anvendelse af disse |
US10471023B2 (en) | 2015-03-12 | 2019-11-12 | British Columbia Cancer Agency Branch | Bisphenol ether derivatives and methods for using the same |
CA2929345A1 (en) | 2015-09-02 | 2017-03-02 | British Columbia Cancer Agency Branch | Co-targeting androgen receptor splice variants and mtor signaling pathway for the treatment of castration-resistant prostate cancer |
US20170298033A1 (en) | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
WO2017210771A1 (en) | 2016-06-06 | 2017-12-14 | British Columbia Cancer Agency Branch | Compounds and compositions for radiation therapy and methods of using the same |
US11485713B2 (en) * | 2018-05-25 | 2022-11-01 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
SG11202103325WA (en) | 2018-10-18 | 2021-05-28 | Essa Pharma Inc | Androgen receptor modulators and methods for their use |
-
2016
- 2016-01-13 DK DK16736999.0T patent/DK3245193T3/da active
- 2016-01-13 NZ NZ733343A patent/NZ733343A/en unknown
- 2016-01-13 WO PCT/CA2016/000008 patent/WO2016112455A1/en active Application Filing
- 2016-01-13 JP JP2017536829A patent/JP6884100B2/ja active Active
- 2016-01-13 ES ES16736999T patent/ES2907708T3/es active Active
- 2016-01-13 AU AU2016206412A patent/AU2016206412B2/en active Active
- 2016-01-13 US US15/543,389 patent/US10654811B2/en active Active
- 2016-01-13 HU HUE16736999A patent/HUE057962T2/hu unknown
- 2016-01-13 EP EP21212648.6A patent/EP3988541A1/en active Pending
- 2016-01-13 EP EP16736999.0A patent/EP3245193B1/en active Active
- 2016-01-13 CA CA2973036A patent/CA2973036A1/en active Pending
-
2017
- 2017-07-10 IL IL253394A patent/IL253394B/en active IP Right Grant
-
2020
- 2020-05-01 US US16/864,479 patent/US11345670B2/en active Active
- 2020-09-14 AU AU2020233630A patent/AU2020233630B2/en active Active
-
2021
- 2021-01-25 JP JP2021009453A patent/JP2021073248A/ja not_active Withdrawn
- 2021-02-16 IL IL280899A patent/IL280899B/en unknown
-
2022
- 2022-04-26 US US17/729,780 patent/US20220267283A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2973036A1 (en) | 2016-07-21 |
AU2016206412B2 (en) | 2020-10-08 |
JP2021073248A (ja) | 2021-05-13 |
EP3245193A1 (en) | 2017-11-22 |
JP2018502867A (ja) | 2018-02-01 |
IL280899A (en) | 2021-04-29 |
EP3245193B1 (en) | 2021-12-08 |
HUE057962T2 (hu) | 2022-06-28 |
IL280899B (en) | 2021-12-01 |
WO2016112455A1 (en) | 2016-07-21 |
EP3245193A4 (en) | 2018-06-20 |
EP3988541A1 (en) | 2022-04-27 |
US20220267283A1 (en) | 2022-08-25 |
JP6884100B2 (ja) | 2021-06-09 |
US20200325106A1 (en) | 2020-10-15 |
NZ733343A (en) | 2022-11-25 |
US10654811B2 (en) | 2020-05-19 |
US11345670B2 (en) | 2022-05-31 |
AU2020233630A1 (en) | 2020-10-15 |
AU2016206412A1 (en) | 2017-07-20 |
US20180327368A1 (en) | 2018-11-15 |
IL253394A0 (en) | 2017-09-28 |
ES2907708T3 (es) | 2022-04-26 |
AU2020233630B2 (en) | 2022-08-11 |
IL253394B (en) | 2021-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3245193T3 (da) | Heterocycliske forbindelser til billedscanning og behandling af cancer samt fremgangsmåder til anvendelse af disse | |
DK3558997T3 (da) | Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer | |
DK3331915T3 (da) | Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere | |
DK3340981T3 (da) | Aryl, heteroaryl og heterocykliske forbindelser til behandling af medicinske forstyrrelser | |
DK3189082T3 (da) | Anti-pd-l1-konjugater til behandling af tumorer | |
DK3227262T3 (da) | Sulfidalkyl og pyridyl-revers-sulfonamidforbindelser til hbv-behandling | |
DK3280441T3 (da) | Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf | |
DK3578547T3 (da) | Sulfonylureaer og relaterede forbindelser og brug af samme | |
DK3258951T3 (da) | Anti-pvrig antistoffer og fremgangsmåder for anvendelse | |
DK3402888T3 (da) | Middel og fremgangsmåder til behandling af hbv | |
DK3119397T3 (da) | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser | |
DK3035926T3 (da) | Forbindelser og fremgangsmåder til behandling af en epilepsilidelse | |
DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
DK3116911T3 (da) | Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse | |
DK3331879T3 (da) | Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne | |
DK3416957T3 (da) | 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes | |
DK3183010T3 (da) | Anordning og tilhørende fremgangsmåde til behandling af medicinsk affald | |
DK3336197T3 (da) | Epigenetiske markører og relaterede fremgangsmåder og midler til detektion og behandling af ovariekræft | |
DK3437359T3 (da) | Fremgangsmåder til at styre relative målinger under nærvær af LBT | |
DK3334497T3 (da) | Indretning til billedstyret fokuseret ultralydsbehandling og sigteapparat | |
DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
DK3310190T3 (da) | Sammensætning til behandling af kød og anvendelse af denne | |
DK3334693T3 (da) | Kontinuerlig fremgangsmåde og system til behandlingen af spildevand | |
DK3468604T3 (da) | Farmaceutiske kombinationer til behandling af cancer |